| Status | Suspended |
| Process | STA pre-2018 |
| Referral date | 01 December 2007 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | 02 October 2008 |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | Sarita Tamber |
| Executive Lead: | Gillian Leng |
| Project manager: | Laura Malone |
| Technical Lead: | Helen Tucker |
Consultees
| Manufacturers / Sponsors | Bristol-Myers Squibb (ixabepilone) |
| Others | Heart of Birmingham Teaching PCT |
| Department of Health | |
| Telfordand Wrekin PCT | |
| Welsh Assembly Government | |
| Patient / Carer Groups | Afiya Trust |
| Age Concern England | |
| Black Health Agency | |
| Breakthrough Breast Cancer | |
| Breast Cancer Campaign | |
| Breast Cancer Care | |
| Breast Cancer UK | |
| Breast Cancer Haven | |
| British Ethnic Health Awareness Foundation (BEHAF) | |
| CANCERactive | |
| Cancerbackup | |
| Cancer Black Care | |
| Cancer Equality | |
| Cancer Voices | |
| Chinese National Healthy Living Centre | |
| Confederation of Indian Organisations | |
| Counsel and Care | |
| Equalities National Council | |
| Helen Rollason Heal Cancer Charity | |
| Help the Aged | |
| IBC UK | |
| Macmillan Cancer Support | |
| Maggie's Centres | |
| Marie Curie Cancer Care | |
| Muslim Council of Great Britain | |
| Muslim Health Network | |
| National Cancer Alliance | |
| National Council for Palliative Care | |
| South Asian Health Foundation | |
| Specialised Healthcare Alliance | |
| Sue Ryder Care | |
| Tenovus Cancer Information Centre | |
| Women's Health Concern | |
| Professional groups | Association of Cancer Physicians |
| Association of Surgeons of Great Britain and Ireland | |
| British Association for Services to the Elderly | |
| British Association of Surgical Oncology | |
| British Geriatrics Society | |
| British Oncological Association | |
| British Psychosocial Oncology Society (BPOS) | |
| Cancer Networks Pharmacists Forum | |
| Cancer Research UK | |
| Royal College of Anaesthetists | |
| Royal College of General Practitioners | |
| Royal College of Nursing | |
| Royal College of Pathologists | |
| Royal College of Physicians' Medical Oncology Joint Special Committee | |
| Royal College of Radiologists | |
| Royal College of Surgeons | |
| Royal Pharmaceutical Society | |
| Royal Society of Medicine - Forum on Intellectual Disabilities | |
| United Kingdom Clinical Pharmacy Association | |
| United KingdomOncology Nursing Society |
Commentators
| Associated Guideline Groups | National Collaborating Centre for Cancer |
| Associated Public Health Groups | None |
| Comparator manufacturer(s) | Eli Lilly & Co Ltd (gemcitabine) |
| Mayne Pharma plc (paclitaxel, vinorelbine) | |
| Medac (UK) (vinorelbine) | |
| Pierre Fabre (vinorelbine) | |
| Roche Products Ltd (capecitabine) | |
| Sanofi-Aventis Ltd (docetaxel) | |
| Teva UK (paclitaxel) | |
| Wockhardt UK Ltd (paclitaxel, vinorelbine) | |
| Evidence Review Group | Evidence Review Group tbc |
| National Coordinating Centre for Health Technology Assessment | |
| General | Age Concern Cymru |
| Board of Community Health Councils in Wales | |
| British National Formulary | |
| Cancer Care Cymru | |
| Department of Health,Social Services and Public Safety for Northern Ireland | |
| Medicines and Healthcare products Regulatory Agency | |
| National Association of Primary Care | |
| National Public Health Service for Wales | |
| NHS Alliance | |
| NHS Confederation | |
| NHS Purchasing and Supply Agency | |
| NHS Quality Improvement Scotland | |
| Scottish Medicines Consortium | |
| Relevant research groups | Against Breast Cancer Research Group |
| Breast Cancer Hope | |
| Breast Cancer Research Trust | |
| Cochrane Collaboration – Cochrane Breast Cancer Group | |
| Institute of Cancer Research | |
| MRC Clinical Trials Unit | |
| National Cancer Research Institute | |
| National Cancer Research Network | |
| Policy Research Institute on Ageing and Ethnicity | |
| Research Institute for the Care of the Elderly |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 9 December 2008 | The manufacturer recently received a negative CHMP opinion for Ixabepilone for locally advanced or metastatic breast cancer. Consequently this appraisal will be suspended until we receive an update from the manufacturer on the status of regulatory approval. |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance